The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://sahilpdwm112227.wikinewspaper.com/4297289/retatrutide_vs_tirzepatide_a_comparative_analysis